Asthma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Asthma Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Asthma; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Asthma receives an overall strategic score of 57/100. The opportunity combines an unmet-need score of 57/100, competition score of 95/100 and market-attractiveness score of 94/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Asthma, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID 15fe4881cb88431eb9d44b018619d7b0 and MeSH identifier D001249. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: Epidemiology of adult asthma within the Hungarian population between 2009 and 2019 – A retrospective financial database analysis Global Epidemiology Epidemiology of adult asthma within the Hungarian population between 2009 and 2019 – A retrospective financial database analysis

Introduction Asthma is the most prevalent non-communicable airway disease, which affected 262 million patients worldwide in 2019, according to the World Health Organization (WHO) with an even higher estimate in recent years according to the Global Initiative of Asthma (GINA) guidelines. [1,2] The prevalence of asthma is high both in childhood and adulthood as well, however large geographical differences can be observed. [3] In Europe, the reported asthma prevalence is 5.86 %, however there is a more than 7 % difference between the highest and lowest reported values on a country level. [3] According to estimations the prevalence of asthma had decreased considerably in the past 30 years in Europe, despite the increase of the prevalent cases of asthma. [4] Similarly, the incidence of asthma also decreased considerably, with a parallel increase in incident cases. [5] However, it is also important to note that reporting of asthma had changed over time multiple times. As multiple definitions had been in circulation and multiple ways of reporting asthma are followed in different countries, providing an ac­ curate estimate proves challenging. [6] Besides available global and regional reports, many countries worldwide and in Europe as well, initiated programs to follow the changes in demographics of asthma. Most of these programs aimed also at improving asthma related health outcomes, recognizing the huge societal effect of the disease. [7] Some of these registries from the largest European countries besides reporting on prevalence, also showed that far from all patients receive pre

Review the underlying epidemiology source

Evidence signal 2: Allergic diseases and asthma Allergic diseases and asthma: a major globalhealth concern

A recent report from the World Allergy Organization, the WAO White Book on Allergy [1], summarizes the burden of allergic diseases world- wide, the risk factors, impact on quality of life of patients, morbidity, mortality, their socio-economic consequences, recommended treatment strategies, future therapies, and the cost–benefit analyses of care services. For instance, asthma prevalence is rising in several high as well as low-income and middle-income countries, and the prevalence and impact of allergic diseases continue to grow. According to the World Health Organization, the number of patients having asthma is 300 million and with the rising trends it is expected to increase to 400 million by 2025. Patients with asthma and allergic diseases have a reduced quality of life. According to the World Health Organization, asthma causes 250 000 deaths annually. Moreover, asthma in infancy often goes unrecognized and thus untreated. In the United States, 23 million people including 7 million children suffer from asthma and the prevalence is increasing. The economic costs of asthma are high both in terms of direct and indirect costs [1] (Table 1), especially in severe or uncon- trolled asthma. In the United States, pediatric asthma results in 14 million missed days of school each year, which in turn result in lost workdays – and lost wages – for caregivers [2]. As asthma continues to affect more children in lower-income countries, this will lead to long-term consequences for their education and perpetuation of their poverty. We need to find ways to control indoor and outdoor air po

Review the underlying epidemiology source

Evidence signal 3: Screening and diagnosis of COPD and asthma based on government guidelines empowering peripheral health workers in Pune district Maharashtra, India: A study protocol Screening and diagnosis of COPD and asthmabased on government guidelines empoweringperipheral health workers in Pune districtMaharashtra, India: A study protocol

The baseline prevalence and annual incidence of confirmed cases of COPD and asthma will be measured at the end of the first year of the study Secondary outcomes The percentage of patients with acute exacerbations of COPD and asthma, the compliance/ medication adherence rate amongst COPD and asthma patients, and the quality of life of the COPD and asthma patients at baseline and for two years using the EQ—5D questionnaire. Statistical analysis planned All statistical Analysis will be done using SPSS software with version 29. Descriptive statistics will show the results of the quantitative variables, and the results of the qualitative variables will be shown by frequency and percentages. Graphs will be added wherever necessary. The chi-square test will test the association between demographic variables, risk factors like smok- ing, occupational exposure, family history, use of biomass fuel, and COPD and asthma. Bivari- ate and multivariate analysis will be done to find the prevalence ratio and adjusted the https://doi-org.libproxy1.nus.edu.sg/10.1371/journal.pone.0308210.g001 https://doi-org.libproxy1.nus.edu.sg/10.1371/journal.pone.0308210.g002 prevalence ratio using logistic regression analysis. A 5% significance level will be used through- out the results. Paired t-test/Wilcoxon sign rank test will be used to test significant mean/ median difference between Quality of life at baseline and yearly follow-up. Ethical issues The final study protocol, including the final version of the other essential documents, is approved by the Institutional Ethics Committee (DHR Reg. No: EC/New/INST/2022/MH/ 0150) approval number B

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Asthma, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Asthma should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: IL-6

IL6 is a potent inducer of the acute phase response. Rapid production of IL6 contributes to host defense during infection and tissue injury, but excessive IL6 synthesis is involved in disease pathology. In the innate immune response, is synthesized by myeloid cells, such as macrophages and dendritic cells, upon recognition of pathogens through toll-like receptors (TLRs) at the site of infection or tissue injury (Probable). In the adaptive immune response, is required for the differentiation of B cells into immunoglobulin-secreting cells. Plays a major role in the differentiation of CD4(+) T cell subsets. Essential factor for the development of T follicular helper (Tfh) cells that are required for the induction of germinal-center formation. Required to drive naive CD4(+) T cells to the Th17 lineage. Also required for proliferation of myeloma cells and the survival of plasmablast cells (By similarity). Acts as an essential factor in bone homeostasis and on vessels directly or indirectly by induction of VEGF, resulting in increased angiogenesis activity and vascular permeability (PubMed:12794819, PubMed:17075861). Induces, through 'trans-signaling' and synergistically with IL1B and TNF, the production of VEGF (PubMed:12794819). Involved in metabolic controls, is discharged into the bloodstream after muscle contraction increasing lipolysis and improving insulin resistance (PubMed:20823453). 'Trans-signaling' in central nervous system also regulates energy and glucose homeostasis (By similarity). Mediates, through GLP-1, crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand (By similarity). Also acts as a myokine (Probable). Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity). Also has a pivotal role in iron metabolism by regulating HAMP/hepcidin expression upon inflammation or bacterial infection (PubMed:15124018). Through activation of IL6ST-YAP-NOTCH pathway, induces inflammation-induced epithelial regeneration (By similarity). Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).

The proposed mechanism anchor for this landscape is IL6. Target selection does not imply that every Asthma patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 8331 matched registered studies overall. The most recent records sampled for this report are:

• CTR20262902 — ZHB107-108舌下片在尘螨过敏引起的成人过敏性鼻炎或鼻结膜炎患者的有效性和安全性研究; status: 进行中 （尚未招募）; phase: Phase 2; sponsor(s): Zonhon Biopharma Institute, Inc.; enrollment: Target enrollment: 国内: 198  Enrolled: 国内: 登记人暂未填写该信息 Actual enrollment: 国内: 登记人暂未填写该信息.
• NCT07757841 — Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis; status: Not yet recruiting; phase: Not Applicable; sponsor(s): Qianfoshan Hospital of Shandong Province; enrollment: 10.
• NCT07752836 — Virtual Breathing Intervention for Enhancing Asthma-related Quality of Life - A Randomized Controlled Trial (BREATHE); status: Not yet recruiting; phase: Not Applicable; sponsor(s): Schön Klinik Berchtesgadener Land SE & Co. KG; enrollment: 110.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Asthma program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

The MCP search identified 6 directly matched recent transaction records. Representative records include:

• RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody (2024-12-23). The record should be reviewed for structure, rights, stage and disclosed economics before it is used as a valuation comparable.
• Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets (2024-11-18). The record should be reviewed for structure, rights, stage and disclosed economics before it is used as a valuation comparable.
• Johnson & Johnson Completes Acquisition of Proteologix, Inc. (2024-05-16). The record should be reviewed for structure, rights, stage and disclosed economics before it is used as a valuation comparable.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Asthma.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Asthma, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that IL6 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Asthma merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where IL6 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Asthma offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.